HC Wainwright Lifts Earnings Estimates for Rockwell Medical

Rockwell Medical, Inc. (NASDAQ:RMTI) – HC Wainwright lifted their Q2 2026 EPS estimates for Rockwell Medical in a research report issued on Thursday, July 9th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.17) per share for the quarter, up from their previous forecast of ($0.20). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is ($0.76) per share. HC Wainwright also issued estimates for Rockwell Medical’s Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.76) EPS, Q1 2027 earnings at $0.05 EPS and FY2027 earnings at $0.43 EPS.

Several other equities research analysts also recently commented on RMTI. Wall Street Zen upgraded shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings downgraded Rockwell Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 15th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $20.00.

Rockwell Medical Stock Performance

Shares of Rockwell Medical stock opened at $5.61 on Monday. The company has a current ratio of 3.74, a quick ratio of 3.43 and a debt-to-equity ratio of 0.23. Rockwell Medical has a 12-month low of $4.89 and a 12-month high of $21.00. The firm has a market capitalization of $22.16 million, a price-to-earnings ratio of -3.74 and a beta of 1.61. The firm’s 50 day simple moving average is $7.00 and its two-hundred day simple moving average is $8.70.

Rockwell Medical (NASDAQ:RMTI) last released its earnings results on Thursday, May 7th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.30). The company had revenue of $17.34 million during the quarter, compared to analyst estimates of $17.95 million. Rockwell Medical had a negative return on equity of 15.41% and a negative net margin of 7.98%.

Hedge Funds Weigh In On Rockwell Medical

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Corsair Capital Management L.P. purchased a new position in Rockwell Medical during the 1st quarter worth approximately $45,000. XTX Topco Ltd lifted its stake in Rockwell Medical by 286.5% during the 4th quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock valued at $52,000 after acquiring an additional 46,029 shares during the period. Jane Street Group LLC purchased a new stake in shares of Rockwell Medical in the 4th quarter valued at $84,000. Geode Capital Management LLC boosted its holdings in shares of Rockwell Medical by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock valued at $304,000 after acquiring an additional 41,668 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Rockwell Medical by 36.5% in the first quarter. Renaissance Technologies LLC now owns 639,120 shares of the company’s stock worth $571,000 after acquiring an additional 170,800 shares during the period. Institutional investors and hedge funds own 23.31% of the company’s stock.

About Rockwell Medical

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.